Iovance posts Q2 product revenue $31.1M; guides FY24 $160-165M, FY25 $450-475M

IOVANCE BIOTHERAPEUTICS, INC.

2024-Q2 EPS reported -$0.76 revenue$31,821,000

Q2 net loss $97.1M ($0.34/shr) vs. $106.5M ($0.47) a year ago; revenue $31.1M from Amtagvi ($12.8M) and Proleukin ($18.3M).
FY24 product revenue guidance $160-165M; FY25 $450-475M; Q3 2024 expected $53-55M.
Over 55 patients infused with Amtagvi since April; >50 ATCs in 29 states; >70 ATCs targeted by year-end.
Cash $449.6M as of July 24, up from $346.3M at Dec 2023, partly from ~$200M ATM equity raise.
Lifileucel pipeline: frontline melanoma TILVANCE-301 enrolling globally; NSCLC Phase 2 accelerating; endometrial cancer Phase 2 started.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.